Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I Gavras

Showing results (71-80 of 166) with videos related to

Pageof 17
Sort By:
Clinical Therapeutics|July 1, 1995
Isradipine versus captopril in patients with essential hypertensionA J Manolis, I Gavras, M Pieprzak, et al.
The Journal of Pharmacy and Pharmacology|December 1, 1991
A novel bradykinin antagonist with improved propertiesB Lammek, Y X Wang, I Gavras, et al.
Journal of Cardiovascular Pharmacology|May 1, 1989
Intravenous dilevalol in the treatment of severe hypertensionM Bursztyn, I Gavras, D J Blasucci, et al.
Peptides|September 1, 1990
A new highly potent antagonist of bradykininB Lammek, Y X Wang, I Gavras, et al.
Journal of Hypertension|June 1, 1985
Sodium chloride-induced partial inhibition in vivo of alpha 2-adrenoceptor agonist functionO Kohlmann, I Gavras, J Biollaz, et al.
Lancet (London, England)|August 10, 1974
Letter: Hypotensive effect of angiotensin-converting-enzyme inhibitor SQ 20,881H Gavras, H R Brunner, I Gavras, et al.
Journal of Clinical Pharmacology|July 1, 1977
The antihypertensive action of methyldopa in relation to its effect on the renin-aldosterone systemH Gavras, I Gavras, H R Brunner, et al.
Journal of Clinical Pharmacology|May 1, 1977
Effect of a new beta-adrenergic blocker, l-bunolol, on blood pressure and on the renin-aldosterone systemH Gavras, I Gavras, H R Brunner, et al.
Kidney International. Supplement|March 1, 1979
Physiologic studies with saralasin in animalsH Gavras, I Gavras, H R Brunner, et al.
Journal of Hypertension|May 1, 1997
Role of vasopressin in essential hypertension: racial differencesG Bakris, M Bursztyn, I Gavras, et al.
Pageof 17

Showing results (71-80 of 166) with videos related to

Sort By:
Pageof 17
Clinical Therapeutics|July 1, 1995
Isradipine versus captopril in patients with essential hypertensionA J Manolis, I Gavras, M Pieprzak, et al.
The Journal of Pharmacy and Pharmacology|December 1, 1991
A novel bradykinin antagonist with improved propertiesB Lammek, Y X Wang, I Gavras, et al.
Journal of Cardiovascular Pharmacology|May 1, 1989
Intravenous dilevalol in the treatment of severe hypertensionM Bursztyn, I Gavras, D J Blasucci, et al.
Peptides|September 1, 1990
A new highly potent antagonist of bradykininB Lammek, Y X Wang, I Gavras, et al.
Journal of Hypertension|June 1, 1985
Sodium chloride-induced partial inhibition in vivo of alpha 2-adrenoceptor agonist functionO Kohlmann, I Gavras, J Biollaz, et al.
Lancet (London, England)|August 10, 1974
Letter: Hypotensive effect of angiotensin-converting-enzyme inhibitor SQ 20,881H Gavras, H R Brunner, I Gavras, et al.
Journal of Clinical Pharmacology|July 1, 1977
The antihypertensive action of methyldopa in relation to its effect on the renin-aldosterone systemH Gavras, I Gavras, H R Brunner, et al.
Journal of Clinical Pharmacology|May 1, 1977
Effect of a new beta-adrenergic blocker, l-bunolol, on blood pressure and on the renin-aldosterone systemH Gavras, I Gavras, H R Brunner, et al.
Kidney International. Supplement|March 1, 1979
Physiologic studies with saralasin in animalsH Gavras, I Gavras, H R Brunner, et al.
Journal of Hypertension|May 1, 1997
Role of vasopressin in essential hypertension: racial differencesG Bakris, M Bursztyn, I Gavras, et al.
Pageof 17